Liposomes Drug Delivery Sales

Liposomes Drug Delivery Sales Market Outlook

The global liposomes drug delivery market is projected to reach approximately USD 10.5 billion by 2035, growing at a remarkable CAGR of around 10.8% from 2025 to 2035. The increasing prevalence of chronic diseases, coupled with the rising demand for targeted drug delivery systems, is a significant factor driving market growth. Moreover, advancements in liposomal formulations and technologies are enhancing the efficacy of existing drugs, leading to a surge in clinical applications. The growing focus on personalized medicine is also promoting the adoption of liposomal formulations, as they can be tailored to improve therapeutic outcomes. These factors collectively create a robust environment for the liposomes drug delivery market to thrive, indicating a promising future for manufacturers and healthcare providers alike.

Growth Factor of the Market

The growth of the liposomes drug delivery market is underpinned by several pivotal factors, each contributing to a more favorable landscape for liposomal products. First, the increasing incidence of cancer and infectious diseases necessitates effective and targeted treatment options, positioning liposomes as a valuable solution. Additionally, the advancements in biotechnology and nanotechnology have enabled the development of more sophisticated liposomal formulations, which can encapsulate a variety of drugs, including large biomolecules. Moreover, the growing emphasis on patient compliance and convenience is driving the demand for liposomal formulations, which often have improved pharmacokinetics and reduced side effects compared to conventional drug delivery methods. Furthermore, regulatory approvals for innovative liposomal formulations are accelerating the introduction of new products in the market. Lastly, the rising investment in research and development activities by pharmaceutical companies to explore novel applications of liposomes in drug delivery systems is expected to fuel market growth in the coming years.

Key Highlights of the Market

• Significant growth projected with a CAGR of 10.8% from 2025 to 2035.
• Increased focus on targeted drug delivery in chronic disease management.
• Advancements in liposomal formulation technologies enhancing drug efficacy.
• Rising prevalence of cancer and infectious diseases driving market demand.
• Growing investment in research and development for novel liposomal applications.

By Product Type

Conventional Liposomes:

Conventional liposomes have been at the forefront of liposomal drug delivery systems since their inception. They are composed of phospholipid bilayers that encapsulate hydrophilic drugs, providing a controlled release mechanism. These liposomes are typically used for delivering various therapeutic agents, including anticancer drugs and antibiotics, owing to their ability to enhance the bioavailability and stability of these compounds. Their simplistic design and ease of formulation make them a popular choice among manufacturers. As research continues to advance, conventional liposomes are being modified to improve their targeting capabilities, which is further propelling their adoption in clinical applications.

PEGylated Liposomes:

PEGylated liposomes, which are modified with polyethylene glycol (PEG), represent a significant innovation in liposomal drug delivery. The inclusion of PEG enhances the circulation time of liposomes in the bloodstream, allowing for prolonged therapeutic effects and reduced clearance by the immune system. This feature makes PEGylated liposomes particularly effective for the delivery of oncology drugs, as they can accumulate in tumor tissues more efficiently due to the enhanced permeability and retention (EPR) effect. As a result, the demand for PEGylated liposomes is steadily increasing, especially in the context of targeted cancer therapies.

Immunoliposomes:

Immunoliposomes are an advanced type of liposomal drug delivery system that incorporates antibodies or ligands on their surface, enabling them to specifically target cells or tissues of interest. This targeted approach is particularly beneficial in cancer therapy, where delivering drugs directly to tumor cells can significantly enhance the therapeutic outcome while minimizing side effects. The market for immunoliposomes is witnessing robust growth as researchers explore their applications in various diseases, including autoimmune disorders and infectious diseases. The specificity and efficacy of immunoliposomes make them a promising avenue for improving drug delivery systems.

pH-Sensitive Liposomes:

pH-sensitive liposomes are designed to release their drug payload in response to changes in pH levels, which is a characteristic feature of many disease environments, particularly tumors and inflamed tissues. By leveraging the acidic microenvironment often found in these areas, pH-sensitive liposomes can enhance drug localization and efficacy while minimizing systemic toxicity. This technology is gaining traction in drug formulation for cancer treatments and has the potential to be applied in various therapeutic areas. The adaptability of pH-sensitive liposomes to target specific sites within the body is a significant factor driving their growth in the market.

Long-Circulating Liposomes:

Long-circulating liposomes are engineered to evade the immune system's detection, allowing them to remain in circulation for an extended period. This characteristic is crucial for maximizing the therapeutic index of drugs used in various treatments, especially oncology and chronic diseases. These liposomes are often modified with specific polymers or surface charges to prolong their circulation time. The growing awareness and research into the benefits of sustained drug release through long-circulating liposomes is leading to increased investment in their development and commercialization, thereby expanding their market share significantly.

By Application

Cancer Therapy:

Cancer therapy remains one of the largest applications for liposomal drug delivery systems, driven by the urgent need for effective treatments that target tumor cells while sparing healthy tissues. Liposomes can encapsulate a wide variety of chemotherapeutic agents and enhance their solubility and stability, leading to improved therapeutic outcomes. Additionally, liposomal formulations can be designed to release their payload in a controlled manner, optimizing drug concentration at the tumor site and reducing systemic side effects. The increasing prevalence of various cancers and the introduction of innovative liposomal formulations are contributing to the robust growth of this segment.

Infectious Disease Treatment:

The treatment of infectious diseases is significantly benefiting from the advancements in liposomal drug delivery systems. Liposomes can encapsulate antibiotics and antifungal medications, improving their bioavailability and therapeutic efficacy. This is particularly crucial in treating resistant infections, where traditional delivery methods may fall short. The flexibility of liposomal formulations allows for the combination of multiple drugs within a single delivery system, enhancing the treatment's effectiveness against complex infections. As the global burden of infectious diseases continues to rise, the demand for liposomal drug delivery systems in this area is expected to grow accordingly.

Immunotherapy:

Immunotherapy represents an exciting frontier in cancer treatment, and liposomes are playing an increasingly vital role in enhancing these therapies. By encapsulating immune-modulating agents within liposomes, researchers can improve the stability, bioavailability, and delivery of these drugs to specific immune cells. The targeted delivery capabilities of liposomes help in minimizing systemic side effects and maximizing therapeutic efficacy. As ongoing research continues to unveil the potential of liposomal formulations in immunotherapy, this application is poised for significant growth in the coming years.

Gene Therapy:

The field of gene therapy has gained considerable momentum, and liposomes are emerging as a promising delivery mechanism for gene-editing technologies and nucleic acids. Liposomes can effectively encapsulate DNA, RNA, and other genetic materials, facilitating their delivery into target cells while protecting them from degradation. This capability is particularly essential in addressing genetic disorders and advancing personalized medicine. As research in gene therapy progresses, the importance of liposomes as a delivery method will likely expand, leading to increased market opportunities in this application segment.

Other Applications:

In addition to the primary applications noted, liposomes have a variety of other therapeutic uses that are gaining traction in the pharmaceutical industry. These include applications in areas like pain management, vaccines, and dermatological treatments, where liposomal formulations can improve drug delivery and efficacy. The versatility of liposomes in formulating both hydrophilic and lipophilic substances allows them to be applied across a broad spectrum of therapeutic areas. As more research is conducted into the benefits of liposomal drug delivery, the scope of these additional applications is likely to expand, further enhancing the market potential.

By Distribution Channel

Hospitals:

Hospitals serve as a critical distribution channel for liposomal drug delivery products, primarily due to their extensive usage in patient treatment regimens. In hospital settings, liposomal formulations are often administered intravenously, particularly for treating cancer and infectious diseases. Hospitals are increasingly adopting innovative liposomal drugs due to their enhanced therapeutic profiles and effectiveness over traditional formulations. The demand within hospitals is also boosted by the rising number of oncology and infectious disease cases, which require effective treatment solutions.

Clinics:

Clinics are becoming an integral part of the distribution network for liposomal drug delivery systems, primarily focused on outpatient treatments for chronic conditions, including cancer. Many specialized clinics are now equipped to administer liposomal drugs, facilitating easier access for patients seeking effective therapies. The convenience of clinic-based treatments, coupled with the rising adoption of personalized medicine approaches, drives the demand for liposomal formulations in these settings. As clinics increasingly recognize the benefits of liposomal drug delivery, their role in the market will likely continue to expand.

Online Pharmacies:

Online pharmacies have emerged as an increasingly prominent distribution channel for liposomal drug delivery products, particularly in light of the growing trend towards e-commerce in healthcare. This channel provides patients with convenient access to medications, including liposomal formulations, allowing them to order their treatments from the comfort of their homes. As online pharmacies continue to gain traction and build trust among consumers, the demand for liposomal drugs through this channel is expected to grow. This trend is especially relevant for patients managing chronic diseases who may require regular medications.

Retail Pharmacies:

Retail pharmacies represent a significant distribution channel for liposomal drug delivery systems, providing patients with direct access to various liposomal formulations. These pharmacies are increasingly stocking liposomal products due to their growing popularity and clinical efficacy. Retail pharmacies play a crucial role in educating patients about the benefits and applications of liposomal therapies, contributing to informed decision-making among consumers. The strategic partnerships between retail pharmacies and pharmaceutical manufacturers further enhance the availability of liposomal products in the market.

Drug Stores:

Drug stores, like retail pharmacies, offer critical access points for patients seeking liposomal drug delivery products. These establishments often carry a range of therapeutic options, including over-the-counter liposomal formulations. The convenience and accessibility of drug stores make them essential for patient care, particularly for those managing chronic conditions with regular medication needs. As awareness of liposomal therapies continues to rise, drug stores are likely to increase their inventory of these specialized products, contributing positively to the overall market growth.

By Ingredient Type

Phospholipids:

Phospholipids are the primary building blocks of liposomal formulations and play a crucial role in determining their structural integrity, stability, and drug encapsulation efficiency. The selection of specific phospholipids can significantly influence the pharmacokinetics and pharmacodynamics of liposomal drugs. With advancements in phospholipid technology, manufacturers are now able to create liposomes that are more targeted and effective in drug delivery. The growing demand for liposomes in various therapeutic applications is driving the market for phospholipids, making them indispensable in the liposomal drug delivery industry.

Cholesterol:

Cholesterol is an essential component of many liposomal formulations, contributing to membrane stability and fluidity. By incorporating cholesterol into liposomes, manufacturers can enhance the drug release profiles and improve the overall performance of the drug delivery system. The usage of cholesterol in liposomal formulations is particularly prominent in oncology, where stability and controlled release are critical for maximizing therapeutic efficacy. The increasing focus on developing sophisticated liposomal formulations is expected to drive the demand for cholesterol in the coming years.

Surface Active Agents:

Surface active agents, or surfactants, are often included in liposomal formulations to enhance their stability and improve drug delivery capabilities. These agents can modify the liposomal surface, allowing for better interaction with biological membranes, thereby facilitating enhanced drug uptake by target cells. As the pharmaceutical industry continues to innovate and explore new liposomal applications, the demand for surface active agents is expected to grow. Their role in optimizing liposomal drug delivery systems positions them as a valuable ingredient in the market.

Other Ingredients:

Other ingredients utilized in liposomal formulations can include stabilizers, preservatives, and targeting ligands that enhance the overall efficacy of the drug delivery system. These ingredients contribute to the customization of liposomal formulations to meet specific therapeutic needs, such as improving shelf life or targeting specific cells. The increasing complexity of liposomal products is driving the demand for a variety of ingredients, as manufacturers seek to formulate innovative therapies that provide better patient outcomes. As the market evolves, the significance of these other ingredients will continue to grow in line with advancements in liposomal technologies.

By Region

The liposomes drug delivery market is witnessing notable growth across various regions, each contributing uniquely to the global landscape. In North America, the market is expected to account for a substantial share, with a projected CAGR of approximately 11.2% from 2025 to 2035. This growth is fueled by the increasing prevalence of chronic diseases, advancements in healthcare infrastructure, and a strong focus on research and development activities. The presence of key pharmaceutical companies and a favorable regulatory environment further enhance the region’s market position, making it a leading player in the liposomes drug delivery sector. Additionally, the rising adoption of innovative therapies, particularly in oncology, is expected to significantly contribute to market growth in this region.

Europe is another significant region for the liposomes drug delivery market, driven by the increasing demand for advanced drug delivery systems and a growing focus on personalized medicine. The region is expected to grow at a healthy CAGR of around 9.5% during the forecast period. Countries like Germany, France, and the UK are at the forefront of biopharmaceutical research and development, leading to a higher adoption of liposomal formulations. Furthermore, the European Union's regulatory framework, which supports innovation in drug delivery technologies, is likely to continue fostering market growth. As awareness of the benefits of liposomal therapies increases, the European market is well-positioned for substantial growth in the coming years.

Opportunities

The liposomes drug delivery market is ripe with opportunities, particularly due to the increasing focus on personalized medicine and targeted therapies. As healthcare continues to evolve towards more tailored treatment strategies, liposomal formulations offer the flexibility and efficacy needed to meet specific patient needs. The ability to encapsulate a wide range of therapeutic agents, from small molecules to large biomolecules, allows for the development of innovative treatment regimens that enhance patient outcomes and compliance. Moreover, as research into the applications of liposomes expands, there is significant potential for new product development in various therapeutic areas, including gene therapy and immunotherapy. This emphasis on personalization and innovation positions liposomes as a key player in the future of drug delivery systems.

Furthermore, the increasing prevalence of chronic diseases, such as cancer and diabetes, is driving demand for effective drug delivery solutions. As the global population ages, the need for advanced therapies that can improve the quality of life for patients continues to grow. Liposomes, with their ability to enhance drug solubility and stability, represent a valuable tool for addressing this demand. Additionally, the rising investments in research and development by pharmaceutical companies to explore novel liposomal formulations indicate a committed effort to capitalize on the opportunities within this market. As collaborative efforts between academia and industry further advance liposomal technology, the potential for innovative applications and market expansion will continue to rise.

Threats

While the liposomes drug delivery market holds significant potential, it is not without its challenges. One of the primary threats facing this industry is the stringent regulatory environment that governs the approval of new liposomal formulations. The process of obtaining regulatory clearances can be lengthy and complex, potentially delaying the introduction of innovative products to the market. Additionally, the high costs associated with research and development, along with the manufacturing complexities of liposomes, may deter smaller companies from entering the market. Moreover, the competitive landscape is becoming increasingly crowded, with numerous players vying for market share. This heightened competition can lead to price wars and reduced profit margins, posing a challenge for manufacturers striving to maintain profitability while delivering high-quality products.

Another notable threat is the potential for adverse reactions associated with liposomal formulations, which can impact patient safety and lead to negative perceptions of these therapies. As with any drug delivery system, there is always a risk of immunogenic reactions or unexpected side effects that could undermine the confidence of healthcare providers and patients alike. Additionally, the rapid pace of innovation in the pharmaceutical industry may lead to the emergence of alternative drug delivery systems that could outperform liposomal technologies in certain applications. It is crucial for companies within the liposomes drug delivery market to remain vigilant and adaptive, continuously investing in research and development to address these threats and maintain their competitive edge.

Competitor Outlook

• Pfizer Inc.
• Johnson & Johnson
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca PLC
• Novartis AG
• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Merck KGaA
• Hikma Pharmaceuticals PLC
• Roche Holding AG
• Sierra Oncology, Inc.
• Seagen Inc.

The competitive landscape of the liposomes drug delivery market is characterized by a diverse range of players, from established pharmaceutical giants to innovative startups. Major companies such as Pfizer, Johnson & Johnson, and Gilead Sciences hold significant market shares due to their extensive research and development capabilities, robust product portfolios, and strong presence in global markets. These companies are continually striving to enhance their liposomal formulations and explore new therapeutic applications to meet the growing demand for effective drug delivery solutions. Additionally, their established distribution networks and collaborations with healthcare providers further bolster their competitive positioning in the market.

Emerging players, including Sierra Oncology and Seagen, are also making their mark on the liposomes drug delivery landscape by focusing on specialized and niche markets. These companies leverage cutting-edge technologies to develop innovative liposomal formulations with unique benefits, catering to specific therapeutic areas. Their agility and focus on research enable them to respond swiftly to market trends and patient needs. Furthermore, the ongoing partnerships and collaborations among industry players and academic institutions are fostering innovation, paving the way for the introduction of novel liposomal products in the near future.

As the liposomes drug delivery market continues to grow, competition is likely to intensify. Companies will need to differentiate their products through advanced formulation techniques, superior efficacy, and enhanced patient experience. The strategic introduction of liposomal products targeting unmet medical needs will be a key focus area for both established and emerging players. As the landscape evolves, monitoring competitor activities and understanding market dynamics will be critical for success in this rapidly changing market environment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Mylan N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Seagen Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Sierra Oncology, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Liposomes Drug Delivery Sales Market, By Application
    • 6.1.1 Cancer Therapy
    • 6.1.2 Infectious Disease Treatment
    • 6.1.3 Immunotherapy
    • 6.1.4 Gene Therapy
    • 6.1.5 Other Applications
  • 6.2 Liposomes Drug Delivery Sales Market, By Product Type
    • 6.2.1 Conventional Liposomes
    • 6.2.2 PEGylated Liposomes
    • 6.2.3 Immunoliposomes
    • 6.2.4 pH-Sensitive Liposomes
    • 6.2.5 Long-Circulating Liposomes
  • 6.3 Liposomes Drug Delivery Sales Market, By Ingredient Type
    • 6.3.1 Phospholipids
    • 6.3.2 Cholesterol
    • 6.3.3 Surface Active Agents
    • 6.3.4 Other Ingredients
  • 6.4 Liposomes Drug Delivery Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Online Pharmacies
    • 6.4.4 Retail Pharmacies
    • 6.4.5 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Liposomes Drug Delivery Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Liposomes Drug Delivery Sales market is categorized based on

By Product Type

• Conventional Liposomes
• PEGylated Liposomes
• Immunoliposomes
• pH-Sensitive Liposomes
• Long-Circulating Liposomes

By Application

• Cancer Therapy
• Infectious Disease Treatment
• Immunotherapy
• Gene Therapy
• Other Applications

By Distribution Channel

• Hospitals
• Clinics
• Online Pharmacies
• Retail Pharmacies
• Drug Stores

By Ingredient Type

• Phospholipids
• Cholesterol
• Surface Active Agents
• Other Ingredients

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Johnson & Johnson
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca PLC
• Novartis AG
• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Merck KGaA
• Hikma Pharmaceuticals PLC
• Roche Holding AG
• Sierra Oncology, Inc.
• Seagen Inc.